Clinical Trial Update: Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

View source ↗

Summary

This non-interventional real-world study assesses afatinib as first-line therapy and subsequent treatments in patients with advanced EGFR mutation-positive lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Gilotrif (Afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Non-squamous, Non-Small Cell Lung Cancer | Status: COMPLETED | Results posted: 2024-12-27